Welcome to our dedicated page for Nexgel Wt Exp 120126 news (Ticker: NXGLW), a resource for investors and traders seeking the latest updates and insights on Nexgel Wt Exp 120126 stock.
NEXGEL, Inc. (NASDAQ: NXGL, warrants: NXGLW) regularly issues news and regulatory updates that highlight its activities in healthcare, beauty and over-the-counter (OTC) hydrogel products, contract manufacturing, and drug delivery initiatives. This news page aggregates those announcements so readers can review how the company describes its progress, partnerships and financial results over time.
Recent press releases have focused on quarterly financial results, where NEXGEL reports revenue, gross profit, operating expenses, net loss and non-GAAP measures such as EBITDA and Adjusted EBITDA. Management commentary in these releases discusses performance in contract manufacturing and consumer branded products, including references to partnerships with organizations like Cintas and STADA, and to consumer demand for brands such as Silly George within the company’s broader portfolio.
NEXGEL’s news flow also includes strategic and corporate developments. The company announced the spin-off of select drug delivery application assets into NexGelRx, an entity that will focus on prescription (Rx) drug delivery solutions using NEXGEL’s proprietary hydrogel technology. Follow-up news detailed strategic investments into NexGelRx from investors associated with Diesis Holdings, LLC and the appointment of a board observer and advisor with experience in reimbursement strategy and healthcare commercialization.
Other announcements cover capital markets transactions, such as registered direct offerings and concurrent private placements of common stock and warrants, as well as expanded partnerships like the agreement with STADA Arzneimittel AG, which includes non-dilutive capital to support product launches and marketing efforts in North America. NEXGEL also issues notices about upcoming earnings calls, conference presentations, and new investor presentations furnished via Form 8-K.
Investors and observers can use this news feed to follow NEXGEL’s own descriptions of its financial performance, hydrogel-based product initiatives, partnership activity and governance decisions, and to track how the company communicates its strategy and operations over time.
NEXGEL (NASDAQ:NXGL) announced that its previously disclosed spin-off, NexGelRx, received strategic investments from Eric Gruntfest and Ariel Imas of Diesis Holdings, LLC on Dec 16, 2025. In connection with the investment, NexGelRx appointed Eric Gruntfest as a board observer and strategic advisor.
Mr. Gruntfest brings over 20 years of experience in reimbursement strategy, payer solutions, and patient access, and currently serves as Managing Partner at Diesis Holdings and CEO of RMBB Health; his background includes senior roles at Medtronic, MiMedx, Shire, and Celgene. Management said his expertise will support commercialization and patient access for NexGelRx’s ultra-gentle hydrogel transdermal delivery products.
NEXGEL (NASDAQ:NXGL) announced the spin-off of select drug delivery assets into a new company, NexGelRx, which will develop prescription drug delivery products using NEXGEL’s hydrogel technology.
Under the agreement NEXGEL will receive a 5% global royalty in perpetuity, retain a 19.99% equity stake in NexGelRx that is non-dilutive for up to $8 million of capital investment, and serve as the exclusive manufacturer of hydrogel for NexGelRx. NexGelRx closed initial outside funding and will focus exclusively on Rx commercialization while NEXGEL remains focused on manufacturing and consumer products.
NEXGEL (NASDAQ: NXGL) reported third quarter 2025 results for the period ended September 30, 2025. Net revenue was $2.93 million, essentially flat year‑over‑year and sequentially. Gross profit was $1.24 million and gross margin improved to 42.4% from 39.3% in Q3 2024. Net loss attributable to NEXGEL stockholders was $0.65 million. EBITDA was ($0.55) million and Adjusted EBITDA was ($0.35) million, with Adjusted EBITDA narrowing sequentially. As of September 30, 2025, cash totaled approximately $938 thousand and restricted cash totaled $920 thousand related to $1 million non‑dilutive capital from STADA. Shares outstanding as of November 11, 2025: 8,143,133.
NEXGEL (NASDAQ:NXGL) will report third quarter 2025 financial results after market close on November 11, 2025. Management will host a conference call the same day at 4:30 P.M. ET to discuss the results and answer questions.
Call details: live dial-in 1-800-579-2543 (U.S. toll free) or 1-785-424-1789 (international); webcast via the company's Events and Presentations page. A replay is available through November 25, 2025 at 1-844-512-2921 (U.S. toll free) or 1-412-317-6671 (international) using code 11160116. An archived webcast will remain available for 90 days.
NEXGEL (NASDAQ: NXGL) announced that CEO Adam Levy will present at the LD Micro Main Event XIX conference in San Diego on October 20, 2025 at 11:30 a.m. PT. The presentation takes place at the Hotel Del Coronado in Track 4 and will be available via webcast.
Investors can access the live webcast at https://ir.nexgel.com/news-events/events-presentations. To request a one-on-one meeting with Mr. Levy during the event, contact KCSA Strategic Communications at Nexgel@KCSA.com.
NEXGEL (NASDAQ: NXGL) reported strong Q2 2025 financial results with revenue reaching $2.88 million, marking a significant 100.3% increase year-over-year. The company achieved substantial margin improvement with gross profit margin expanding to 43.6% from 20.3% in Q2 2024.
Key highlights include a reduced net loss of $0.67 million (vs. $0.89 million in Q2 2024) and improved Adjusted EBITDA of ($0.42) million. Post-quarter, NEXGEL secured a $1 million non-dilutive advance from STADA and raised $1.05 million in additional financing. The company maintains its 2025 guidance of $13 million in revenue and expects to achieve positive EBITDA during the year.
NEXGEL (NASDAQ: NXGL), a provider of ultra-gentle hydrogel products for healthcare and consumer applications, will release its Q2 2025 financial results on August 12, 2025, after market close.
The company will host a conference call at 4:30 P.M. ET on the same day. Investors can join via phone at 1-800-274-8461 (U.S.) or 1-203-518-9814 (International). A replay will be available through August 26, 2025, and the webcast will be archived for 90 days.
NEXGEL (NASDAQ: NXGL), a provider of medical and OTC hydrogel products, has appointed Steve Ciardiello, CPA, to its Board of Directors. As the current Chief Accounting Officer of Shutterstock (NYSE: SSTK), Ciardiello brings over 25 years of senior finance executive experience.
Ciardiello's expertise includes financial leadership, strategic execution, and corporate governance in high-growth public companies. At Shutterstock, he leads a global finance team managing SEC reporting, tax, internal audit, and general accounting. His background includes implementing financial transformation initiatives and over 15 years of Big 4 public accounting experience.
NEXGEL (NASDAQ: NXGL), a provider of medical and OTC hydrogel products, has announced a $950,000 registered direct offering at $2.30 per share, issuing 413,044 shares of common stock. The company is also conducting a concurrent private placement of unregistered warrants to purchase up to 206,522 shares at an exercise price of $4.25 per share.
The warrants will be exercisable immediately upon issuance with a five-year term. This financing, combined with their current cash position and a recent $1 million non-dilutive advance from STADA, aims to strengthen NEXGEL's balance sheet as they prepare for anticipated growth in the second half of the year. Alere Financial Partners, LLC served as the exclusive placement agent for the offering.
NEXGEL (NASDAQ: NXGL), a provider of medical and OTC hydrogel products, announced its CEO Adam Levy will participate in the 6th Annual CEO Networking Event hosted by Semco Capital. The event will take place on June 2, 2025 in Chicago, featuring a fireside chat with Scott Weis.
The networking event brings together microcap companies with strong management teams and growth potential. Interested investors can contact Scott Weis for attendance information.
FAQ
What is the current stock price of Nexgel Wt Exp 120126 (NXGLW)?
